Lykos Therapeutics is a biotechnology company focused on developing novel therapies and therapeutic approaches to treat mental health conditions, with an initial emphasis on PTSD. It leverages decades of evidence-based research to catalyze new treatment options and aims to destigmatize conversations around mental health while improving accessibility. As a public benefit corporation, Lykos prioritizes positive impact on patients, communities and society, operating with a global outlook in mental healthcare innovation.
No recent deals for this company.